Protein-Based Therapeutics and Drug-Delivery Platforms

Human plasma proteins possess several characteristics that make them attractive biomaterials for therapeutic applications, including their biocompatibility, biodegradability and established clinical use.

Vivekbiopharma is developing technologies that use proteins such as human serum albumin, fibrinogen and thrombin as functional components of advanced therapeutic and drug-delivery systems.

Our current research focuses on two complementary approaches:

1. Modulation of chemotherapy-associated inflammation using an albumin-based therapeutic strategy

2. Localised and sequential delivery of anticancer drugs using an in situ-forming fibrin depot

Both technologies are being developed toward preclinical validation and future clinical translation..

Intellectual Property
& Innovation Pipeline

IPR 1

Composition for Attenuating Paclitaxel-Induced Inflammatory Response

Therapeutic Rationale

The technology is being developed to:

• attenuate paclitaxel-associated inflammatory responses;

• provide an adjunctive strategy without broadly suppressing immune function;

• potentially reduce cumulative dependence on corticosteroids during anticancer therapy;

• enable biomarker-guided management of patients exhibiting elevated inflammatory responses;

• investigate modulation of systemic inflammatory phenotypes associated with triple-negative breast cancer (TNBC); and

• explore peri-operative modulation of tumour-promoting inflammatory environments.

The proposed composition is intended for intravenous administration as an adjunct to systemic chemotherapy.

The platform builds on Vivekbiopharma's expertise in human serum albumin-based drug conjugation and represents an emerging therapeutic strategy at the intersection of drug delivery, oncology and immunomodulation.

Systemic chemotherapy remains central to cancer treatment, but chemotherapy-associated inflammatory responses can contribute to treatment-related morbidity and may adversely influence the tumour microenvironment and therapeutic response.

Vivekbiopharma has developed an albumin-based therapeutic approach designed to modulate paclitaxel-associated inflammatory responses.

The technology combines a human serum albumin–curcumin conjugate (AlbCur) with albumin-paclitaxel (AlbTax). The AlbCur component is designed to exert biological activity at very low concentrations and is being investigated as an adjunct to systemic anticancer therapy.

IPR 2

Two-Component Fibrin-Based Depot for Sequential Drug Release

How the Technology Works

The platform consists of two components:

Component I: Fibrinogen containing albumin-associated paclitaxel

Component II: Thrombin containing cisplatin or carboplatin

The two components are delivered using a dual-syringe delivery system and mixed immediately before or during administration.

When the components interact, thrombin converts fibrinogen into fibrin, rapidly creating an insoluble, biodegradable drug-loaded depot at the
treatment site.

The resulting fibrin matrix entraps both anticancer agents.

Sequential Drug Release

The system is engineered to generate two distinct drug-release phases.

Early phase:
The relatively freely diffusible platinum drug—cisplatin or carboplatin—is released first.

Sustained phase:
Albumin-associated paclitaxel is retained within the fibrin matrix and released more gradually.

This sequential or biphasic release strategy is designed to maintain localised drug exposure while potentially reducing unnecessary systemic exposure.

Potential Applications

The technology is being developed for localised administration, including peritumoral, intratumoral and post-surgical tumour-bed applications.

Potential indications include:

• breast cancer, including triple-negative breast cancer;

• head and neck cancers;

• melanoma;

• sarcoma; and

• other accessible solid tumours where localized therapy may provide clinical benefit.

The platform is envisioned as a ready-to-use two-component kit coupled with a controlled dual-syringe delivery system.

Systemically administered anticancer drugs distribute throughout the body, potentially causing significant off-target toxicity while limiting the duration of therapeutically effective drug concentrations at the tumour site.

Vivekbiopharma is developing an injectable, biodegradable fibrin-based depot for localized and sequential delivery of established anticancer drugs directly at or around a tumour site.

Why Localized Cancer Therapy?

Conventional systemic chemotherapy is highly effective for many cancers but exposes healthy tissues to cytotoxic drugs along with the tumour.

Localized drug delivery offers a different therapeutic opportunity: maintaining effective concentrations of established anticancer agents at the site where they are most needed while potentially reducing systemic exposure.

Vivekbiopharma's fibrin-depot programme combines three established biological and pharmaceutical principles:

Biocompatible fibrin matrix + clinically established anticancer drugs + controlled local delivery

Rather than developing a new cytotoxic molecule, our approach seeks to improve how proven anticancer agents are delivered and retained at the target site.

Innovation

Transforming proven biological materials and medicines into smarter therapeutic platforms.

CONTACT

admin@vivekbiopharma.com

+91 9447046727

© 2026. All rights reserved.